Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Morales, Eva
• dc.contributor.author Cots, Francesc
• dc.contributor.author Sala, Maria
• dc.contributor.author Comas Serrano, Mercè
• dc.contributor.author Belvis, Francesc Xavier
• dc.contributor.author Riu Camps, Marta
• dc.contributor.author Salvadó, Margarita
• dc.contributor.author Grau Cerrato, Santiago
• dc.contributor.author Horcajada Gallego, Juan Pablo
• dc.contributor.author Montero, Maria Milagro
• dc.contributor.author Castells, Xavier
• dc.date.accessioned 2025-01-13T08:52:48Z
• dc.date.available 2025-01-13T08:52:48Z
• dc.date.issued 2012
• dc.description.abstract Background: We aimed to assess the hospital economic costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. Methods: A retrospective study of all hospital admissions between January 1, 2005, and December 31, 2006 was carried out in a 420-bed, urban, tertiary-care teaching hospital in Barcelona (Spain). All patients with a first positive clinical culture for P. aeruginosa more than 48 h after admission were included. Patient and hospitalization characteristics were collected from hospital and microbiology laboratory computerized records. According to antibiotic susceptibility, isolates were classified as non-resistant, resistant and multi-drug resistant. Cost estimation was based on a full-costing cost accounting system and on the criteria of clinical Activity-Based Costing methods. Multivariate analyses were performed using generalized linear models of log-transformed costs. Results: Cost estimations were available for 402 nosocomial incident P. aeruginosa positive cultures. Their distribution by antibiotic susceptibility pattern was 37.1% non-resistant, 29.6% resistant and 33.3% multi-drug resistant. The total mean economic cost per admission of patients with multi-drug resistant P. aeruginosa strains was higher than that for non-resistant strains (15,265 vs. 4,933 Euros). In multivariate analysis, resistant and multi-drug resistant strains were independently predictive of an increased hospital total cost in compared with non-resistant strains (the incremental increase in total hospital cost was more than 1.37-fold and 1.77-fold that for non-resistant strains, respectively). Conclusions: P. aeruginosa multi-drug resistance independently predicted higher hospital costs with a more than 70% increase per admission compared with non-resistant strains. Prevention of the nosocomial emergence and spread of antimicrobial resistant microorganisms is essential to limit the strong economic impact.
• dc.format.mimetype application/pdf
• dc.identifier.citation Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012 May 23;12:122. DOI: 10.1186/1472-6963-12-122
• dc.identifier.doi http://dx.doi.org/10.1186/1472-6963-12-122
• dc.identifier.issn 1472-6963
• dc.identifier.uri http://hdl.handle.net/10230/69085
• dc.language.iso eng
• dc.publisher BioMed Central
• dc.relation.ispartof BMC Health Serv Res. 2012 May 23;12:122
• dc.rights © 2012 Morales et al.; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/2.0
• dc.subject.keyword Antimicrobial resistance
• dc.subject.keyword Economic analysis
• dc.subject.keyword Hospital cost
• dc.subject.keyword Multi-drug resistance
• dc.subject.keyword Pseudomonas aeruginosa
• dc.title Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion